BACKGROUND/ PURPOSE: Children receiving extracorporeal membrane oxygenation (ECMO) for respiratory failure can have significant fluid overload and renal insufficiency. Addition of inline continuous venovenous hemofiltration (CVVH) could provide additional benefits in fluid management compared to use of standard medical therapies with ECMO. METHODS: Patients with pediatric respiratory failure receiving ECMO with CVVH were case-matched to similar patients receiving ECMO without CVVH to compare fluid balance, medication use, and clinical outcomes. RESULTS: Twenty-six of eighty-six patients with pediatric respiratory failure on ECMO (30%) received CVVH for >24 h (median 7.5 days on CVVH). Survival was not significantly different between patients receiving CVVH and those who did not receive CVVH (P = 0.51). For ECMO survivors receiving CVVH, overall fluid balance was less than that in non-CVVH survivors (median 25.1 ml kg(-1) day(-1); range -40.2 to 71.2 vs. 40.2, 1.1 to 134.9; P = 0.028). Time to desired caloric intake was faster in patients receiving CVVH (1 day, 1-5) than in patients who did not receive CVVH (5 days; 1-11; P < 0.001). Patients receiving CVVH-ECMO also received less furosemide (0.67 vs. 2.11 mg kg(-1) day(-1); P = 0.009). CONCLUSIONS: Use of CVVH in ECMO was associated with improved fluid balance and caloric intake and less diuretics than in case-matched ECMO controls.
BACKGROUND/ PURPOSE:Children receiving extracorporeal membrane oxygenation (ECMO) for respiratory failure can have significant fluid overload and renal insufficiency. Addition of inline continuous venovenous hemofiltration (CVVH) could provide additional benefits in fluid management compared to use of standard medical therapies with ECMO. METHODS:Patients with pediatric respiratory failure receiving ECMO with CVVH were case-matched to similar patients receiving ECMO without CVVH to compare fluid balance, medication use, and clinical outcomes. RESULTS: Twenty-six of eighty-six patients with pediatric respiratory failure on ECMO (30%) received CVVH for >24 h (median 7.5 days on CVVH). Survival was not significantly different between patients receiving CVVH and those who did not receive CVVH (P = 0.51). For ECMO survivors receiving CVVH, overall fluid balance was less than that in non-CVVH survivors (median 25.1 ml kg(-1) day(-1); range -40.2 to 71.2 vs. 40.2, 1.1 to 134.9; P = 0.028). Time to desired caloric intake was faster in patients receiving CVVH (1 day, 1-5) than in patients who did not receive CVVH (5 days; 1-11; P < 0.001). Patients receiving CVVH-ECMO also received less furosemide (0.67 vs. 2.11 mg kg(-1) day(-1); P = 0.009). CONCLUSIONS: Use of CVVH in ECMO was associated with improved fluid balance and caloric intake and less diuretics than in case-matched ECMO controls.
Authors: Herbert P Wiedemann; Arthur P Wheeler; Gordon R Bernard; B Taylor Thompson; Douglas Hayden; Ben deBoisblanc; Alfred F Connors; R Duncan Hite; Andrea L Harabin Journal: N Engl J Med Date: 2006-05-21 Impact factor: 91.245
Authors: Charlene M T Robertson; Juzer M Tyebkhan; Abraham Peliowski; Philip C Etches; Po-Yin Cheung Journal: Acta Paediatr Date: 2006-02 Impact factor: 2.299
Authors: Robyn J. Meyer; Patrick D. Brophy; Timothy E. Bunchman; Gail M. Annich; Norma J. Maxvold; Theresa A. Mottes; Joseph R. Custer Journal: Pediatr Crit Care Med Date: 2001-07 Impact factor: 3.624
Authors: Geoffrey M Fleming; David J Askenazi; Brian C Bridges; David S Cooper; Mathew L Paden; David T Selewski; Michael Zappitelli Journal: ASAIO J Date: 2012 Jul-Aug Impact factor: 2.872
Authors: David T Selewski; Timothy T Cornell; Neal B Blatt; Yong Y Han; Theresa Mottes; Mallika Kommareddi; Michael G Gaies; Gail M Annich; David B Kershaw; Thomas P Shanley; Michael Heung Journal: Crit Care Med Date: 2012-09 Impact factor: 7.598
Authors: Heidi J Murphy; John B Cahill; Katherine E Twombley; David J Annibale; James R Kiger Journal: J Artif Organs Date: 2017-10-30 Impact factor: 1.731
Authors: Geoffrey M Fleming; Rashmi Sahay; Michael Zappitelli; Eileen King; David J Askenazi; Brian C Bridges; Matthew L Paden; David T Selewski; David S Cooper Journal: Pediatr Crit Care Med Date: 2016-12 Impact factor: 3.624